Aytu Biopharma, Inc.
AYTU
$1.27
$0.010.79%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.13% | -7.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.13% | -7.80% | |||
| Cost of Revenue | 18.44% | -14.06% | |||
| Gross Profit | -10.00% | -5.15% | |||
| SG&A Expenses | -9.86% | -2.74% | |||
| Depreciation & Amortization | 0.00% | -29.32% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.72% | -10.95% | |||
| Operating Income | -158.90% | 81.73% | |||
| Income Before Tax | -74.50% | 138.19% | |||
| Income Tax Expenses | -169.88% | -41.73% | |||
| Earnings from Continuing Operations | -39.16% | 123.67% | |||
| Earnings from Discontinued Operations | -67.72% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.54% | 131.93% | |||
| EBIT | -158.90% | 81.73% | |||
| EBITDA | -24.98% | 11.88% | |||
| EPS Basic | -47.10% | 129.56% | |||
| Normalized Basic EPS | -26.30% | 8,938.46% | |||
| EPS Diluted | -66.10% | 80.76% | |||
| Normalized Diluted EPS | -20.17% | 5,926.92% | |||
| Average Basic Shares Outstanding | 1.06% | 7.98% | |||
| Average Diluted Shares Outstanding | -6.75% | 61.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
